Patients, Caregivers and Advocates

SANRECO STUDY

The SANRECO study includes two parts:

  • Part 1, also known as phase 1, was designed to determine the safety and the correct dose/amount of SLN124
  • Part 2, also known as phase 2, is evaluating how well SLN124 works and how often it should be given

The main endpoints of the study are to assess:

  • The reduction of phlebotomy requirements with SLN124 treatment
  • The effect of SLN124 in reducing PV related symptoms and improving quality of life measures
  • The safety and whether SLN124 works in PV patients

Silence Therapeutics is currently enrolling patients with polycythaemia vera (PV) for the SANRECO phase 2 study.

What To Expect When Participating In The Phase 2 Study

Before Treatment Starts
  • Talk to your haematologist to see if you are suitable to participate in the study as they can provide you with more information about taking part
  • Upon consent for study participation, you will undergo complete clinical assessments to ensure it is safe to participate
  • Each study centre will work to make sure the process is as easy as possible and will provide help and support throughout the assessment process
Study Overview
Study Overview
  • You will receive either SLN124 or placebo by injection (under the skin) every 6 weeks
  • Neither you nor the study team will know which treatment you’re receiving at first—this is to ensure fairness in the results
  • Here’s what to expect:
    • Placebo-controlled Period – 36 weeks (approximately 9 months): You’ll get SLN124 or placebo by random assignment. Neither you nor your doctor will know which one you receive
    • Extension Period: You will either continue or switch to SLN124
    • Open-label Period: All participants receive SLN124
How the Study Medication is Being Evaluated
How the Study Medication is Being Evaluated
  • The main goal is to see if SLN124 helps keep red blood cell levels normal without the need for phlebotomies
  • Researchers will also track:
    • Quality of life measurements during the study
    • How much SLN124 is in the blood
    • Any side effects
Before Treatment Starts
Visits and Time Commitment
  • The SANRECO phase 2 study will last nearly 4 years
  • You will be seen at the study site clinic every 6 weeks to receive treatment, check your health and response to treatment – these visits can take up to 4 hours
Safety Monitoring and Care
Safety Monitoring and Care
  • You will have regular health check-ups, including lab tests and physical exams
Support and Reimbursement
Support and Reimbursement
  • You will be cared for by a team of medical professionals
  • There’s no cost to join and participate in the SANRECO study
  • There are no study-related care, medication or medical expense costs
  • Travel costs will be reimbursed, and accommodation will be included where needed
  • Refreshments and meals are included when attending the study site clinic

More information about SANRECO can be found here.

SANRECO
SLN124 Phase 1 Results

SLN124 Phase 1 Results

  • Early results from the completed phase 1 portion of the study show SLN124 was well-tolerated with no major safety concerns1
  • Patients needed fewer phlebotomies following infrequent dosing of SLN124, when compared to the 12 months prior to the start of treatment1

1. Kremyanskaya, Marina, et al. Initial results from a phase 1/2 study evaluating SLN124, a novel galnac conjugated siRNA, in patients with polycythaemia vera (SANRECO). Blood. 2024;144(suppl 1):656. doi:10.1182/blood-2024-205854